Physician profile
Steven R Bailey
NPI 1003921909
$305,384.47
in general payments reported to CMS, 2019-2025
22 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $15K · 2021: $23K · 2022: $36K · 2023: $61K · 2024: $61K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $169K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $168,585.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,437.50 |
| Food and Beverage | $853.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $233,644.82 | 2019-2025 | Mitraclip, Amplatzer Amulet, Jeti All In One Non-Sterile Kit |
| Jenavalve Technology, INC. | $51,697.64 | 2019-2025 | Jenavalve Pericardial Tavr System |
| Boston Scientific Corporation | $18,578.14 | 2019-2025 | Clinical Trial Product |
| Medtronic Vascular, INC. | $560.41 | 2019-2020 | |
| Edwards Lifesciences Corporation | $122.78 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.39 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $97.19 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $90.64 | 2019-2021 | |
| Osprey Medical INC | $88.61 | 2020 | |
| Biotronik INC. | $85.57 | 2019 | |
| Cvrx, INC. | $72.40 | 2024 | Barostim Neo System |
| Vifor Pharma, INC. | $35.11 | 2022 | |
| Pfizer INC. | $29.16 | 2022 | |
| Medtronic, INC. | $26.44 | 2022 | |
| Ge Healthcare | $24.54 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $23.03 | 2023 | Acthar |
| Siemens Medical Solutions USA, INC. | $21.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.12 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $18.51 | 2022 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $16.89 | 2019 | |
| Quidel Corporation | $16.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.